Today’s Research Reports on Centric Health, Emblem, OrganiGram and Acerus Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Centric Health Corp.
https://rdinvesting.com/news/?ticker=CHH.TO

Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V

OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V

Acerus Pharmaceuticals Corp.
https://rdinvesting.com/news/?ticker=ASP.TO

Centric Health’s stock had no change Friday, to close the day at $0.295. The stock recorded a trading volume of 145,527 shares, which was below its three months average volume of 220,185 shares. In the last year, Centric Health’s shares have traded in a range of 0.25 – 0.82. The share price has gained 18.00% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $0.376 is below its 200-day moving average of $0.476. Shares of the company are trading at a Price to Earnings ratio of 32.78. Shares of Centric Health have fallen approximately 42.31 percent year-to-date.

Access RDI’s Centric Health Corp. Research Report at:
https://rdinvesting.com/news/?ticker=CHH.TO

On Friday, shares of Emblem recorded a trading volume of 376,024 shares, which was below the three months average volume of 426,000 shares. The stock ended the day 1.33% lower at 1.48. The share price has gained 25.42% from its 52-week low with a 52-week trading range of 1.18 – 26.32. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $1.50 is below its 200-day moving average of $1.66. Shares of Emblem have fallen approximately 35.09 percent year-to-date.

Access RDI’s Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V

OrganiGram’s stock moved 1.99% lower Friday, to close the day at $4.92. The stock recorded a trading volume of 385,245 shares, which was below its three months average volume of 627,766 shares. In the last year, OrganiGram’s shares have traded in a range of 2.00 – 5.68. The share price has gained 146.00% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.41 is greater than its 200-day moving average of $4.21. Shares of OrganiGram have gained approximately 20 percent year-to-date.

Access RDI’s OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V

On Friday, shares of Acerus Pharmaceuticals recorded a trading volume of 40,540 shares, which was below the three months average volume of 177,182 shares. The stock ended the day 2.94% higher at 0.35. The share price has gained 250.00% from its 52-week low with a 52-week trading range of 0.10 – 0.52. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.35 is greater than its 200-day moving average of $0.30. Shares of Acerus Pharmaceuticals have gained approximately 20.69 percent year-to-date.

Access RDI’s Acerus Pharmaceuticals Corp. Research Report at:
https://rdinvesting.com/news/?ticker=ASP.TO

Our Actionable Research on Centric Health Corp. (TSX: CHH.TO), Emblem Corp. (TSX-V: EMC.V), OrganiGram Holdings Inc. (TSX-V: OGI.V) and Acerus Pharmaceuticals Corp. (TSX: ASP.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 501651